Derazantinib - CISMeF

Preferred Label : Derazantinib;

NCIt definition : An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Derazantinib binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells. FGFR, a receptor tyrosine kinase, is upregulated in many tumor cell types and plays a key role in tumor cellular proliferation, differentiation, angiogenesis and survival.;

UNII : N9B0H171MJ;

InChIKey : KPJDVVCDVBFRMU-AREMUKBSSA-N;

CAS number : 1234356-69-4;

Molecule name : ARQ 087; ARQ-087;

NCI Metathesaurus CUI : CL445613;

ChEBI ID : CHEBI:63453;

Details

Origin ID

C104267;

UMLS CUI

C4682391;

Automatic exact mappings (from CISMeF team)
- ARQ 087 [MeSH concept]
- derazantinib [MeSH Supplementary Concept]
Currated CISMeF NLP mapping
- derazantinib [MeSH concept]
- derazantinib [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- derazantinib [MeSH Supplementary Concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Fibroblast Growth Factor Receptor Family [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients